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The matrix proteins aggrecan 
and fibulin-1 play a key role in 
determining aortic stiffness
Yasmin 1, Raya Al Maskari  1, Carmel M. McEniery1, Sarah E. Cleary1, Ye Li2, Keith Siew  1, 
Nichola L. Figg3, Ashraf  W. Khir2, John R. Cockcroft4, Ian B. Wilkinson1 & Kevin M. O’Shaughnessy  1
Stiffening of the aorta is an important independent risk factor for myocardial infarction and stroke. Yet 
its genetics is complex and little is known about its molecular drivers. We have identified for the first 
time, tagSNPs in the genes for extracellular matrix proteins, aggrecan and fibulin-1, that modulate 
stiffness in young healthy adults. We confirmed SNP associations with ex vivo stiffness measurements 
and expression studies in human donor aortic tissues. Both aggrecan and fibulin-1 were found in the 
aortic wall, but with marked differences in the distribution and glycosylation of aggrecan reflecting 
loss of chondroitin-sulphate binding domains. These differences were age-dependent but the striking 
finding was the acceleration of this process in stiff versus elastic young aortas. These findings suggest 
that aggrecan and fibulin-1 have critical roles in determining the biomechanics of the aorta and their 
modification with age could underpin age-related aortic stiffening.
Stiffening of the large arteries such as the aorta (arteriosclerosis) has several important adverse haemodynamic 
consequences, including widening of the pulse pressure and altered shear stress. These promote vascular and 
cardiac remodelling, and ultimately cause increased cardiovascular (CV) endpoints. Aortic pulse wave velocity 
(aPWV) is the gold-standard measure of stiffness. It is also an important independent predictor of clinical CV 
outcomes1, including myocardial infarction, heart failure and stroke2,3 which make it an attractive target for ther-
apeutic intervention.
Like most cardiovascular traits, aortic stiffness has a multi-factorial aetiology and a polygenic pattern of inher-
itance (~40% heritability). This reflects the impact of many genes that influence processes such as cell signalling, 
the cytoskeleton, mechanical regulation of vascular structure4, and vascular smooth muscle tone5. Nonetheless, 
dissecting genetic influences is challenging and the precise molecular players and pathways remain elusive. A 
GWAS meta-analysis by the AortaGen consortium, identified several genetic variants on chromosome 14 that 
strongly associate with aortic stiffness6, but this locus lies in a gene desert with BCL11B (1 MB telomeric from the 
locus) as a the most plausible candidate in the region. However, the biological significance of this GWAS signal 
is still unclear.
To date, all the genetic studies on stiffness have focused on older adults (>45 years)6, so the observed asso-
ciations may relate to environmental exposures (e.g. smoking and hypertension) and atherosclerosis. However, 
with ageing, arteries stiffen as a consequence of a number of processes including elastin degradation, extracellu-
lar matrix (ECM) remodelling, calcification of the elastic lamellae, vascular smooth muscle cell senescence and 
apoptosis, inflammation and oxidative stress7–9. So, to identify genetic risk alleles for stiffness it is key to study 
relatively young people to isolate ‘pure’ genetic contribution and minimise atherosclerotic related influences10,11. 
To this end, we have performed a candidate-gene based association study using the phenotypic extremes from 
a cohort of young healthy adults (the ENIGMA cohort) with low cardiovascular risk. To do this, we chose sub-
jects with low versus high aPWV values and compared them using tagging single nucleotide polymorphisms 
(tagSNPs) to efficiently capture the genetic information from the linkage disequilibrium (LD) or haplotype blocks 
of the genes of interest12. We then validated significant associations in the remaining ENIGMA subjects. Finally, 
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we correlated validated SNPs with an ex vivo stiffness measurement in human donor aortic tissues and explored 
the tissue expression of these SNPs and their encoded proteins (the study plan is shown in Fig. 1).
Results
SNP Analysis in ENIGMA. We performed genetic association studies using a discovery cohort pre-selected 
for extremes of aPWV from the ENIGMA study. The discovery subjects represented the top and bottom 12% of 
the study (n = 240 in each extreme group), and tagSNPs were from genes correlated with arterial wall properties in 
the gene profiling study by Durier et al.4 and other published studies5 (Supplementary Table 1, see Supplementary 
Material for references). We found that the two groups in the primary study chosen based on their extreme aPWV 
were actually well matched for age, gender, body mass index and systolic pressure (Table 1). However, diastolic 
and mean pressures, heart rate and aPWV were significantly different between the two extreme groups.
Figure 1. Study Flow. Design and samples investigated.
Parameters Study Groups Significance level (p)
Top* Bottom*
Age (y) 21 ± 3 20 ± 2 ns
Male/Female (n) 120/120 120/120 ns
Non-Smokers (n) 233 232 —
Alcohol-Non drinkers (n) 25 30 —
BMI (kg/m2) 23 ± 4 22 ± 3 ns
SBP (mmHg) 118 ± 14 116 ± 13 ns
DBP (mmHg) 69 ± 8 67 ± 8 0.015
MAP (mmHg) 83 ± 9 81 ± 9 0.011
Heart Rate (bpm) 69 ± 11 66 ± 11 0.004
aPWV (m/s) 6.76 ± 0.65 4.53 ± 0.33 <0.001
Total cholesterol (mmol/l) 4.34 ± 0.9 3.88 ± 0.8 <0.001
HDL (mmol/l) 1.45 ± 0.4 1.42 ± 0.4 ns
LDL (mmol/l) 2.4 ± 0.9 2.1 ± 0.7 <0.001
Triglycerides (mmol/l) 1.16 ± 0.7 0.91 ± 0.6 <0.001
Glucose (mmol/l) 4.88 ± 1.6 4.77 ± 0.70 ns
Table 1. Baseline characteristics of ENIGMA cohort. Data presented as mean ± SD. ns = Not significant. BMI- 
Body mass index; SBP-systolic blood pressure; DBP-diastolic blood pressure; MAP-mean arterial pressure; 
HDL-high density lipoprotein; LDL-low density lipoprotein; aPWV-aortic pulse wave velocity. *Refers to Top 
and Bottom deciles of the cohort.
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Of the 384 tagSNPs genotyped (Supplementary Table 2), we identified 35 SNPs in 20 genes that signifi-
cantly associated with aPWV with an unadjusted p-value of <0.05. Of these, 12 tagSNPs in 9 genes (Aggrecan 
(ACAN), Erythrocyte membrane protein band 4.1-like 2 (EPB41L2), Fibulin-1 (FBLN-1), Fibrinogen (FBG), 
Interleukin-18 (IL-18), Integrin, alpha6 (ITAG6), Integrin, beta 3 (ITGB3), Matrix metalloproteinase-3 (MMP-3), 
Figure 2. ACAN Gene. Genomic map and protein domains with linkage disequilibrium (LD) plot and tagSNPs 
genotyped.
Figure 3. FBLN-1 Gene. Genomic map with linkage disequilibrium (LD) plot showing tagSNPs genotyped.
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Figure 4. The aPWV is associated with ACAN and FBLN-1 gene polymorphisms. There is a significant allele 
dose-effect for each of the ACAN and FBLN-1 SNPs, with homozygotes for CC (A), GG (B), GG (C), AA (D) 
and AA (E) having the largest aPWV. *P < 0.001.
Model Parameters Standardised coefficient (Beta) Significance level (p) R Square change (%)
Dependent variable: aPWV
ACAN Gene Polymorphisms
  MAP 0.51 <0.001 36
  Age 0.17 <0.001 2
  Heart rate 0.13 <0.001 1
  rs2882676 A/C 0.11 0.003 1
Adjusted R2 value = 0.40; F = 74.670; p < 0.001
  MAP 0.50 <0.001 36
  Age 0.18 <0.001 2
  Heart rate 0.16 <0.001 1
  rs2293087 T/G 0.09 0.027 1
Adjusted R2 value = 0.41; F = 66.715; p < 0.001
  MAP 0.52 <0.001 36
  Age 0.17 <0.001 2
  Heart rate 0.12 0.003 1
  rs3743399 G/A 0.05 0.151 —
Adjusted R2 value = 0.39; F = 72.336; p < 0.001
FBLN-1 Gene Polymorphisms
  MAP 0.51 <0.001 36
  Age 0.16 <0.001 2
  Heart rate 0.13 <0.001 1
  rs2018279 A/T 0.09 0.003 1
Adjusted R2 value = 0.40; F = 73.250; p < 0.001
  MAP 0.52 <0.001 36
  Age 0.17 <0.001 2
  Heart rate 0.12 0.002 1
  rs2238823 A/G 0.08 0.003 1
Adjusted R2 value = 0.40; F = 70.204; p < 0.001
Table 2. ACAN and FBLN-1 gene polymorphisms independently associate with aPWV.
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and Nitric oxide synthase (NOS)), remained significant with a Bonferroni-adjusted p-value of <0.00013 
(Supplementary Table 3). We selected five SNPs tagging the two extracellular matrix (ECM) proteins, namely 
Aggrecan and Fibulin-1, as the most plausible biological candidate molecules for further studies, as these two genes 
were most up-regulated and associated with aPWV in a previous gene profiling study4. Three SNPs in ACAN that 
tagged adjacent LD blocks (chromosome 15; rs2882676A/C in exon 13, rs2293087T/G in intron 3, rs3743399A/G in 
exon 12; Fig. 2), and two SNPs in FBLN-1 (chromosome 22; rs2018279A/T in intron 2, rs2238823A/G in intron 8; 
Fig. 3) correlated significantly with aPWV in subjects pre-selected for extremes of aPWV values.
Association of ACAN and FBLN-1 Polymorphisms with aPWV. In the discovery cohort, aPWV 
associated significantly with all three ACAN polymorphisms. Average aPWV values were significantly higher 
in subjects carrying the rs2882676/CC, rs2293087/GG, and rs3743399/GG alleles, and a significant allele 
dose-effect was observed for all three polymorphisms (Fig. 4A–C). Since rs2882676/CC, rs2293087/GG, 
rs3743399/GG homozygotes had significantly higher aPWV, a stepwise multiple linear regression analysis was 
performed with additive allele dose models including the main known confounders for velocity (age, mean 
arterial pressure, heart rate). This analysis showed that the rs2882676/C and rs2293087/G alleles independently 
predicted aPWV with an adjusted R2 of approximately 40% (p < 0.001) for the model, but the rs3743399 poly-
morphism did not (Table 2).
FBLN-1 polymorphisms also correlated significantly with aPWV in the ENIGMA discovery cohort 
(Fig. 4D,E). Mean aPWV values were lower in rs2018279/TT and rs2238823/GG allele carriers compared to 
Figure 5. ACAN gene polymorphisms associate with aortic stiffness and gene expression. (A), (C) Elastic 
modulus compared to rs2882676 and rs2293087 genotypes. CC and GG donors had stiffer arteries compared 
to AA and TT ones (*P = 0.024, **P > 0.05). (B), (D) Transcript expression pattern of rs2882676 and rs2293087 
across the three genotypes (*P = 0.04, **P > 0.05). Bar graph represents the mean ± SEM of ACAN transcript, 
normalized against GAPDH.
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their respective homozygotes. Again, assuming an additive inheritance pattern, stepwise regression analysis was 
performed for aPWV adjusting for main confounding variables, which confirmed that both polymorphisms inde-
pendently predicted aPWV (adjusted R2 of 40%, p < 0.001, Table 2).
Figure 6. FBLN-1 gene polymorphisms relationship with aortic stiffness and gene expression. (A), (C) Elastic 
modulus compared to rs2018279 and rs2238823 genotypes. (B), (D) Transcript expression level of rs2018279 
and rs2238823 polymorphisms. Bar graph represents the mean ± SEM of FBLN-1 gene expression normalized 
against GAPDH. *P > 0.05.
Parameters Low EM* (n = 32) High EM*(n = 28) Significance level (p)
Age (years) 51 ± 11 66 ± 14 <0.001
Male/Female (n) 17/15 18/10 ns
Elastic Modulus (MPa) 0.08 ± 0.01 0.37 ± 0.10 <0.001
BMI (kg/m2) 28 ± 5 28 ± 6 ns
SBP (mmHg) 119 ± 25 130 ± 24 ns
DBP (mmHg) 69 ± 15 64 ± 13 ns
Serum Creatinine at retrieval (µmol/l) 129.2 ± 88.2 111.5 ± 69.1 ns
Glucose (mmol/l) 9.37 ± 4.09 9.47 ± 3.84 ns
Non-Smokers (n) 10 12 ns
Alcohol-Non drinkers (n) 15 12 ns
Hypertension (n) 10 14 —
Diabetes (n) 4 3 —
CVD (n) 2 5 —
Table 3. Baseline characteristics of aortic tissue donors. Data presented as mean ± SD. ns = Not significant. 
BMI- Body mass index; SBP-systolic blood pressure; DBP-diastolic blood pressure. *Refers to the Top and 
Bottom 15% of the donors.
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Figure 7. Transcript levels. (A) ACAN and (B) FBLN-1 in donor aortas (n = 52) that showed either low or high 
elastic modulus (EM) ex vivo. Bars represent mean ± SEM of ACAN and FBLN-1 gene expression normalized 
against GAPDH. *P < 0.05.
Figure 8. Aggrecan tissue and protein distribution in young (<32 y) versus older (>60 y) aortic tissue donors. 
(A) Representative sections showing immunohistochemical staining for the G1-G2 domain of aggrecan in 
the medial layer. Scale bar, 50 μm. (B) Top panel: Quantification plot shows aggrecan protein levels are down-
regulated in older donors as compared to younger donors. Each dot on the scatter plot exemplifies the signal 
intensities of individual donor samples. Bars represent mean signal intensity normalized against β-actin. 
*P = 0.026. Middle panel: Representative western blots showing the expression of the chondroitin-sulfate (CS) 
attachment region of aggrecan in young versus older donors. Bottom panel: Schematic diagram illustrates the 
degradation of C-terminal aggrecan fragments and their diffusion out of the vessel wall with increasing age, 
accompanied by an accumulation of G1 fragments. CS, chondroitin-sulfate; LP, link protein. (C) Representative 
immunofluorescent staining of aortic tissue shows uniform expression of aggrecan G3 domain (green) across 
the vessel wall of younger donors that is largely absent from older ones. Scale bar, 50 μm.
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Similar SNP trends and associations were observed for each of the ACAN and FBLN-1 SNPs in the replication 
ENIGMA subset and in the combined dataset. But as expected, the discovery cohort with extreme aPWV values 
showed bigger genotypic differences for aPWV compared to the replication subset with mid-range values (Fig. 1) 
and the combined dataset (Supplementary Table 3).
Studies in Human Aortic Tissue Samples. To further explore our SNP findings from the ENIGMA 
cohort, we genotyped four tagSNPs that predicted aPWV in the human donor aortic tissue samples (age range 
17–83 years) collected through our NHSBT transplant coordinators in Cambridge. We also measured ACAN 
mRNA levels for rs2882676 that best predicted aPWV (Table 2) to see if it was an eSNP.
Figure 9. Aggrecan protein domain distribution in young versus old aortas and in high versus low EM donors. 
(A) Representative immunohistochemical staining for G1 domain comparing young (<32 y) versus old donors 
(>60 y), and in aortas with low and high EM. (B), (C) Representative western blots showing quantitative analysis of 
aggrecan-CS signal intensities, normalized against β-actin in independent young and old donor samples with high 
EM (n = 5, 2 young and 3 old) and low EM (n = 5, 2 young and 3 old) values. Each dot on the scatter plot exemplifies 
the signal intensities of individual donor samples. Solid bars are the mean signal intensity in the plot. *P < 0.05.
Figure 10. Heat-map distribution of aggrecan protein G3 domain immunostaining in young (<32 y) versus 
old donors (>60 y), and in low versus high elastic modulus donor aortas. Representative immunofluorescence 
staining shows higher G3 deposits in young aortas with low EM compared to high EM samples; and in old 
aortas with low EM compared to high EM group. Heat map scale bar 0 to 1 demonstrates the aggrecan protein 
distribution and intensity in each sample and in each group. Scale bar, 50 μm.
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ACAN and FBLN-1 SNPs, mRNA and Protein Expression in the Aorta. We next looked for correla-
tion of SNP genotypes with an ex vivo measurement of aortic stiffness. The ‘elastic modulus’ (EM) directly corre-
lates to PWV, and all four polymorphisms showed similar trends in the human aortic rings as aPWV did in the 
ENIGMA cohort. However, this trend was only significant for the rs2882676 exon 13 ACAN SNP, where donors 
homozygous for the rs2882676/C allele had higher EM values indicating stiffer arteries (Fig. 5A). The CC allele 
Figure 11. Distribution of elastin fibers in young (<32 y) versus old (>60 y), and in low versus high EM donor 
aortas. With aging and increased stiffness, elastic fibers are frayed and fragmented. Scale bar, 50 μm.
Figure 12. Fibulin-1 tissue and protein distribution in young versus older donor aortas. (A) Representative 
immunohistochemical staining showing the pattern of FBLN-1 distribution in aortic sections from a young 
(<32 y) versus an old donor (>60 y). Fibulin-1 is expressed throughout the vessel wall but appears denser in 
the intima and adventitial side of media in young aorta compared to the more even distribution in the older 
aorta. Scale bar, 50 μm. (B) Representative western blot comparing fibulin-1 protein expression in young and 
old donors. (C) Quantitative analysis of fibulin-1 signal intensities, normalized against β-Actin in young (n = 6) 
versus old donor tissues (n = 7). Each dot on the scatter plot exemplifies the signal intensities of individual 
donor samples. Solid bar is the mean intensity. *P = 0.008.
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carriers for this SNP also showed significantly lower (1.7-fold) ACAN mRNA expression as compared to those 
homozygous for A allele (Fig. 5B), confirming that this SNP was a functional eSNP.
Conversely, donors with the ACAN rs2293087 SNP or the FBLN-1 SNPs, rs2018279 and rs2238823 genotype, did 
not have significantly different EM or mRNA levels compared to their respective homozygotes (Figs 5C,D and 6).
Association of ACAN and FBLN-1 Gene Expression with EM in Aortic Rings. To further define the 
functional role of ACAN and FBLN-1, we looked at transcript abundance in the extremes from the EM distribu-
tion i.e. top and bottom 15% respectively (low EM and high EM). Donors in the stiffer high EM group were older, 
and had higher systolic blood pressure compared to the low EM group (Table 3). According to the donor records, 
less than 10.6% were on CVD drugs. The high EM had a significantly lower expression of ACAN mRNA (2.3-fold) 
compared to the low EM group (Fig. 7A), which persisted after correcting for age as a confounder (ANCOVA, 
p < 0.05). The high EM donor aortas also showed significantly lower FBLN-1 transcript levels (3.8-fold) compared 
to their low EM counterparts (Fig. 7B). Again the difference held after adjusting for age (ANCOVA, p = 0.01).
Protein and Tissue Distribution of ACAN and FBLN-1 with Age and EM. Many ECM proteins 
including aggrecan are altered or degraded with age. We therefore, explored aggrecan protein expression patterns 
in the aortic wall using antibodies that recognized epitopes on the three main domains. Namely, the N-terminal 
G1-G2 domain, the chondroitin-sulphate (CS) middle region and the C-terminal G3 domain (see schema in 
Fig. 8). Immunohistochemical staining showed that aggrecan G1-G2 and G3 domains were present throughout 
the vessel wall layers of young subjects (Fig. 8A–C). However, in older subjects, a striking deposition of G1-G2 
domain staining was seen across the medial layer with a marked loss of immunofluorescent intensity for G3 
domain staining (Fig. 8C). This indicated an age-dependent loss of the C-terminals from aggrecan and accumu-
lation of N-terminal fragments in the aortic wall, which mirrors the changes reported in joint cartilage with age13. 
These CS fragments are necessary for viscoelasticity and we confirmed their loss by western blotting aortic wall 
homogenates. This confirmed a 3.5-fold reduction (Fig. 8B) in immunoblottable CS in the older group (n = 5) 
compared to the younger group (n = 5).
We next compared aggrecan protein expression patterns in independent young and old donor aorta samples 
based on their ex vivo elasticity (top and bottom 15% of EM values). Interestingly, we found that G1-G2 staining 
pattern was more typical of the older aortas (p < 0.05, Fig. 9A), and the stiff young donor aortas (high EM) had 
the lowest expression of CS region as compared to the elastic aortas ((low EM), Fig. 9B,C)). Young distensible aor-
tas (low EM) also expressed strikingly more G3 compared to both older and stiffer aortas (high EM). This pres-
ervation of intact aggrecan molecules was best seen using a heat map (Fig. 10). Of note, the G3 staining inversely 
related to aortic elastin disorganisation (Fig. 11).
Figure 13. Fibulin-1 protein distribution in aortas with low and high EM. (A) Immunoblotting shows the 
fibulin-1 protein expression pattern in the high and low EM groups. (B) Quantification plot shows fibulin-1 
protein levels are lower in high EM group as compared to low EM group (n = 5 in each group). Each dot on the 
scatter plot exemplifies the signal intensities of individual donor samples. Bars represent mean signal intensity 
normalized against β-actin. *P = 0.029.
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When fibulin-1 protein expression patterns were examined in tissues from younger (<32 yrs) and older 
(>60 yrs) donor aortas, the protein was evident across all layers of the vessel wall in both age groups (Fig. 12A). 
However, fibulin-1 expression was more prominent in the tunica intima and adventitial side of media in the 
younger donors (Fig. 12A). Immunoblotting of whole aortic lysates also showed that total fibulin-1 was actually 
higher in young donors versus old donors (p = 0.008, Fig. 12B,C), indicating age-related changes. Moreover, 
when the difference in fibulin-1 protein expression between low and high EM aortic homogenates was assessed, 
we found significantly reduced fibulin-1 protein levels in the high EM group as compared to the low EM group 
(p = 0.029, Fig. 13A,B), signifying fibulin-1 protein also alters with increased stiffness.
Discussion
The extracellular matrix (ECM) plays a central role in both the age-related remodelling of the vessel wall and 
its response to hypertension or injury. As proteoglycans are key components of the ECM and hence wall stiff-
ness14, we focused on ACAN and FBLN-1 amongst the hits from our discovery study. Aggrecan is a protein best 
understood from its role in joint cartilage where its domain structure and function has been extensively inves-
tigated; especially its contribution to the viscoelastic properties of cartilage15. Mutations in ACAN have been 
linked to monogenic human skeletal disorders such as osteochondritis dissectans (OMIM 165800)16 and spon-
dyloepiphyseal dysplasia (OMIM 612813), and VNTR polymorphisms with premature degenerative lumbar disk 
degeneration17,18 and osteoarthritis itself19,20. We found the exonic (rs2882676/C) and intronic (rs2293087/G) 
tagSNPs associate significantly with higher aPWV values in our young subjects. Additionally, we found the exonic 
rs2882676 SNP modulates the elastic modulus (EM), an ex vivo measurement of stiffness in human donor aortic 
tissues. The tagSNPs we used were on different domains: the intronic rs2293087 was in the G1 region; the exonic 
synonymous rs3743399 and non-synonymous rs2882676 were in chondroitin sulphate (CS) attachment and G3 
regions respectively. The latter coding for EGF-like domains involved in the Ca2+ binding process15. Prior to 
this work a biological role for these domains in the vasculature was not suggested, but aggrecan has now been 
linked with vascular dementia, and increased aortic stiffness is associated with small vessel disease in the brain21. 
More recently, Suna et al. demonstrated the role of aggrecan and aggrecanase activity in a pig model of the injury 
response to intracoronary stenting22. In a separate study, the same authors also showed that aggrecan protein was 
more abundant in human coronary artery and thoracic aorta versus veins, and showed that the cells responsible 
for aggrecan and aggrecanase activity expression were in fact the vascular smooth muscle cells. This new data 
strongly implicates a role for aggrecan in vascular plasticity and arterial remodelling.
Carriage of the ACAN rs2882676/C allele was an independent predictor of aortic stiffness (aPWV) in this 
study even after removing the influence of typical confounding factors. This SNP changes the amino acid from 
glutamine to alanine at position 1508 (E1508A), and non-synonymous SNPs are often assumed to be functional 
especially in cases where the substitution changes resides in an important domain or motif in a protein23. We do 
not know if this is the case for the E1508A substitution in aggrecan, but the same SNP was identified in a GWAS 
as a risk allele for late-onset Alzheimer’s disease24. We have also shown that it affects ACAN transcript levels and 
associates with ex vivo aortic stiffness.
The N-terminal G1 domain of aggrecan interacts with hyaluronan and a link protein, forming a stable com-
plex anchoring the aggrecan molecule to the tissue. Glycosaminoglycans (GAGs) bind to the large central G2 
domain of aggrecan that typically carries keratin sulphate (KS) and >100 chondroitin sulphate chains per mole-
cule. Negative charge provided by these sulphate groups attracts counter ions and draws water into the extracel-
lular matrix. Aggrecan thus gives viscoelasticity and load-bearing properties to tissues in which it is expressed. 
So heterogeneous distribution of proteoglycans such as aggrecan across the aortic wall is probably crucial in 
regulating the residual stress of the aorta25. Aggrecan structure and expression does not remain constant at other 
sites throughout life. For instance, in human articular cartilage, intervertebral disc and sclera, aggrecan undergoes 
an age-dependent proteolysis resulting in a progressive loss of its C-terminal and accumulation of N-terminal 
G1 fragments13,26–28. For the first time, we show that a similar age-dependent process of aggrecan degradation 
occurs in the human aortic vessel wall. We also show that ACAN transcript abundance declines with age and is 
significantly lower in individuals with stiffer aortas (high EM). In line with our findings, transcript abundance of 
ACAN and other proteoglycan core proteins falls in the aortas of adult mice compared to late stage embryos29. The 
total GAG content in human thoracic aorta also decreases after the age of 4030 and is lower in non-atherosclerotic 
ascending aortas of old subjects compared to younger ones31. Intriguingly, Manley et al. observed a higher num-
ber of amino-acids associated with CS chains in old aortic samples compared to younger ones31: approximately 2 
serine molecules per GAG chain in older subjects and 1 serine molecule per GAG chain in younger subjects. We 
suspect that the fragmentation of aortic aggrecan exposes additional sites on CS chains for attachment with serine 
residues. Conversely, our data conflicts with previous findings by Durier et al.4, who reported increased ACAN 
transcript abundance in association with increased aPWV. This discrepancy may reflect their very small sample 
size (n = 9) and heterogeneity of the samples taken from coronary artery bypass grafting patients (>50 yrs).
The age-dependent loss of aortic aggrecan may partly be explained by reduced synthesis of the protein (from 
reduced transcript levels), as suggested by a notable decline in transcript levels after the fifth decade (Fig. 14). 
However, the accumulation of G1 fragments in the medial layer of older subjects implicates post-translational 
modifications of ECM components. Aggrecan is degraded by a number of proteases including disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMST-4,5), matrix metalloproteinases (MMP-1,2,3,8,9,13), 
cathepsins and calpains32. The CS and inter-globular domain regions are particularly susceptible to proteolytic 
cleavage27. In the aorta, aggrecan degradation is likely to be due to increase in the activity and expression of aor-
tic MMP-2, MMP-9 and Calpain-1 with advancing age33–37, whilst increased ADAMTS levels promote thoracic 
aortic aneurysm progression38.
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The proteolytic degradation of aggrecan and reduced ACAN expression could contribute to the stiffening of 
aorta in several ways. Firstly, GAGs such as aggrecan, are involved in the load-bearing properties of tissues. To 
achieve this, aggrecan forms large complexes with other matrix proteins such as Fibulin, Tenascin and Lumican, 
which are restrained in the tissue by a scaffold of collagen fibrils that contributes to the ECM organization28,39,40. 
Loss of aggrecan functionality could therefore impact on viscoelasticity, medial ECM disorganization and col-
lagen fibril redistribution to modulate vessel stiffness. Secondly, the concomitant accumulation of G1 fragments 
in the medial layer may further promote its degeneration and pathological ECM remodelling. Lastly, the deg-
radation of aggrecan weakens its intrinsic ability to suppress calcium phosphate formation41. It is highly likely 
that aortic wall mineralization, another driver of aortic stiffness, is facilitated by aggrecan fragmentation and 
degradation42.
The fate of the cleaved G3 and CS fragments in the aorta remains to be established but are potentially impor-
tant. They may be released into the circulation, where they could provide a novel biomarker for aortic stiffness. 
Although this may be difficult to distinguish from the signal caused by the fragments exiting joint cartilage with 
age. This hypothesis is supported by the presence of GAGs in old aortas that were digested ex vivo31. A better 
understanding of the precise mechanisms regulating aggrecan decline could also identify novel therapeutic tar-
gets. These might be aimed at either restoring aortic aggrecan content or preventing its proteolytic degradation. 
Current strategies targeting aggrecan include the use of aggrecan analogues resistant to proteolysis in articu-
lar cartilage repair43, aggrecanase inhibitors to improve cardiac function in pressure overload models44, and the 
development of specific ADAMTS-4/5 inhibitors45,46. All have undergone clinical trials for osteoarthritis47, and 
could be plausibly repurposed as therapeutic strategies for aortic stiffness.
Fibulin-1 is an ECM protein present throughout the arterial wall, but its expression is highest in the outermost 
layer of the tunica media in association with external elastic lamina48,49. Nevertheless, the clinical significance 
of fibulin-1 gene (FBLN-1) in the vasculature remains unclear. There are, for example, no clear associations of 
FBLN-1 with human disease, but there is evidence linking FBLN-5 with altered biomechanical and microstruc-
tural properties in animal models50. Besides being an ECM protein, fibulin-1 circulates in high concentrations 
in plasma and is a cardiovascular disease biomarker reflecting elastolysis51,52. It is also associated with heart fail-
ure53, severe aortic stenosis54, vascular calcification55, up-regulated in non-atherosclerotic diabetic tissues51, and 
affected by arterial wall mechanics4. Moreover, fibulin-1 up-regulation is linked with increased stiffness56 and 
kidney disease52, whilst its down-regulation is related to aortic dissection57,58. Fibulin-1 levels are also affected 
by drug interventions, so patients treated with spironolactone show reduced levels in parallel with regression of 
vascular remodelling59.
Given the relation of fibulin-1 with elastic fibres in the vessel wall, it is perhaps not a surprise that we found 
associations between aPWV and intronic fibulin-1 polymorphisms (rs2018279, rs2238823) in this study. They 
are also independent predictors of aPWV. The SNPs themselves are not eSNPs, so thay are either affecting expres-
sion of other transcripts or in LD with other functional SNPs. Expression of fibulin-1 transcript and protein 
was down-regulated in donors with stiff aortas and aortas from older donors had significantly lower fibulin-1 
protein expression than younger ones. This is the same pattern we saw with aggrecan, but may not be coinci-
dental. Fibulin-1 is a high affinity ligand for the G3 domain of aggrecan60, so reduction in fibulin-1 expression 
may, at least in part, be explained by the loss of aggrecan from the vessel walls. Our data are in accord with the 
observations found in tissues recovered from acute aortic and Stanford type A dissections, where fibulin-1 was 
down-regulated57,58. Age-related elastin fragmentation and medial degeneration are the hallmarks of aortic stiff-
ness leading to aortic dissection, which presumably explains the parallel loss of fibulin-1. Fibulin-1 is thought to 
interact with elastin and microfibrils, and therefore plays a role in elastic fibrogenesis contributing to the struc-
tural integrity of the vessel wall48. Currently, it is not clear whether the observed decline in fibulin-1 expression 
contributes to the age-related fraying and fragmentation of elastin fibres or is a consequence of it. Further studies 
are needed to address this key point.
In summary, we demonstrate for the first time that common polymorphisms in the genes for aggrecan and 
fibulin-1 predict aortic stiffness in young healthy subjects. We also show that stiff young donor aortic tissue has 
changes in the expression and distribution of these proteins that are more typical of stiff old aortic tissue. So, loss 
Figure 14. Transcript expression pattern of ACAN across age decades. Bars represent mean ± SEM normalized 
against GAPDH.
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and degradation of these proteins appear to be important drivers for age-related aortic stiffening (ARAS) and 
modulating these changes could slow or arrest the aortic stiffening process.
Methods
Study participants. A total of 2000 subjects who participated in the ENIGMA study between 2002–2007, 
and a part of the Anglo Cardiff Collaborative Trial (ACCT)61, and aged between 18 and 30 years, were studied as 
part of an investigation into the physiological factors relating to the development of hypertension in young adults. 
Individuals were selected at random from the Universities of Swansea and Cambridge, UK by advertisement and 
word of mouth. Subjects from this cohort who were <25 years old were used for the genetic studies. A small num-
ber of subjects with systolic and/or diastolic hypertension (SBP/DBP ≥140/90 or diastolic ≥90 mmHg), diabetes 
or hypercholesterolemia (total cholesterol ≥6.5 mmol/L) were excluded from this age-restricted ENIGMA subset, 
as were subjects receiving any cardiovascular medication. The Local Research Ethics Committees (LREC/01/203), 
approved the study, and written informed consent was obtained from all participants. All experiments were per-
formed in accordance with the relevant guidelines and regulations.
All samples and donor data were handled in accordance with the policies and procedures of the Human Tissue 
Act (UK). The Local and Regional Ethics Committees approved the study (MREC/03/2/074).
Haemodynamic measurements. All studies were conducted in a quiet temperature-controlled room. 
Height and weight were recorded, and body mass index was calculated. After 10 minutes supine rest, peripheral 
blood pressure was recorded in the dominant arm using a validated oscillometric device (HEM-705CP; Omron 
Corporation). Carotid and femoral artery waveforms were recorded with a high fidelity micromanometer (SPC-
301; Millar Instruments) using the SphygmoCor system (AtCor Medical), as previously described62. aPWV was 
calculated from the foot-to-foot delay between carotid and femoral waveforms and body surface measurements 
that adjusted for parallel transmission in the carotid and aorta by using the suprasternal notch as a fiducial point as 
described previously. All measurements were made in duplicate, and mean values used in the subsequent analysis.
Laboratory measurements. Blood samples were drawn, serum and plasma separated and stored at −80 °C. 
Total cholesterol, triglycerides, and glucose were determined using standard methodology in an accredited labo-
ratory. Genomic DNA (gDNA) was extracted from the venous blood using the commercial kit in accordance with 
the manufacturers protocol (Invitrogen, Lifetech Biosciences). The quality and quantity of gDNA was determined 
using Nanospectrophotometer and PicoGreen methods and samples stored at −80 °C freezer until further analysis.
Genetic association studies in ENIGMA. tagSNPs selection. 31 genes from gene expression profiling 
work done by Durier et al.4 and 22 genes previously associated and/or implicated with aPWV and/or arterial wall 
properties5,63 were investigated (Supplementary Table 1). Details of the genes, SNPs and their selection, and the 
genotyping criteria followed are described in Supplementary Material. Briefly, the tagSNPs (n = 384) for each 
gene were selected from the public databases, including the International HapMap project64, SeattleSNPs data-
base65, and previously published candidate gene/SNP association studies.
Primary study. A total of 384 tagSNPs were genotyped in 480 ENIGMA study participants using the custom 
designed VeraCode GoldenGateTM assays on Illumina BeadArray platform (Illumina Inc., San Diego, USA). 
Supplementary Table 2 presents detailed information of the 384 tagSNPs. Illumina system uses a high density 
BeadArray technology in combination with allele specific extension, adapter ligation and amplification assay pro-
tocol. The technology uses two alternative oligo probes that bind specifically to one or other of the two possible 
SNP alleles, and a third oligo probe that is locus specific, downstream to the allele-specific oligo of approximately 
1–20 base pairs from the SNP sequence used to query each SNP. Briefly, 5 ul of 50 ng of biotinylated DNA was 
bound to paramagnetic beads and mixed with a pool of SNP-specific oligonucleotides for annealing. The oligonu-
cleotides that hybridized were then extended and ligated to generate DNA templates which were amplified using 
universal fluorescently-labeled primers. Single-stranded PCR products were then hybridized to a Sentrix® Array 
Matrix and the arrays were imaged using a BeadArray Reader Scanner. All samples were genotyped in duplicate 
in the same array/plate and also a number of samples were repeated in different plates. Genotypes were called 
using the GenCall data analysis software (Illumina Inc., San Diego, USA). In some SNPs where the genotype clus-
ters were unambiguous, manual calling was performed. Majority of the SNPs genotyped were in Hardy Weinberg 
Equilibrium (HWE) and the SNP call rate was 99.98%.
Genotyping strategy. This was performed in two stages: first, subjects selected according to the top (n = 240) and 
bottom (n = 240) deciles of aPWV values were genotyped using a custom designed assay (Fig. 1, Supplementary 
Table 2). This strategy was chosen as risk alleles for stiffness can be identified in the phenotype extremes, and also 
to reduce the cost of genotyping. In the second stage, SNPs/loci that passed a significant threshold (p < 0.05) were 
further pruned down with bonferroni correction and only those SNPs that were highly significant (p < 0.00013, 
Supplementary Table 3), and belonged in particular, to the extracellular matrix (ECM) i.e., Aggrecan and 
Fibulin-1 genes were selected for genotyping, as these genes were up-regulated and associated with aPWV in the 
gene profiling work.
Replication study of ACAN and FBLN-1 polymorphisms. In total, five polymorphisms: three in aggre-
can (rs3743399, rs2882676, rs2293087) and two in fibulin-1 (rs2018279, rs2238823) genes were validated in the 
remainder of the ENIGMA cohort (group with mid-range aPWV values, n = 1233, after excluding participants 
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with aPWV values of <3.5 and missing data) using the ABI Taqman 7500 Sequence Detecting System and SNP 
genotyping assays (Applied Biosystems, USA).
Briefly, Taqman technology uses two alternative oligomer probes that bind specifically to one or other of 
the two possible SNP alleles. Briefly, 100 ng of gDNA was mixed with 2x Taqman Universal Master Mix, No 
AmpErase UNG, labelled probe (FAM and VIC dye-labelled) and MQ H2O to a total volume of 15 µL for each 
sample. The SNP is PCR amplified and during PCR, each probe binds to its target allele and the fluorescent 
reporter dye (which is different to each probe) is cleaved and released into solution by the 3′→5′ exonuclease 
activity of the Taq polymerase. Reporter dye intensity at the end of PCR reaction was then used to quantify 
levels of each SNP in the sample. The PCR thermal cycling conditions involved an initial denaturing at 95 °C for 
10 minutes, followed by 40 cycles at 95 °C for 15 seconds and 60 °C for 1 minute. Allelic discrimination was carried 
out by detecting allele specific fluorescence and data was analyzed off-line with the sequence detection software 
(version 1.9).
Validation study of ACAN and FBLN-1 proteins in human aortic tissue samples. Since significant 
associations were observed between aortic stiffness and ACAN and FBLN-1 gene variants in the primary and rep-
lication studies in the ENIGMA cohort, we investigated the actual role of these proteins in the vasculature by using 
‘the aortae’, and performed SNP genotyping, gene and protein expression studies. Additionally, immunohistochem-
ical / immunoflourescence studies were also carried to identify the tissue distribution in this arterial tissue (Fig. 1).
Aortic tissue sample collection. Human aortic tissue samples (n = 232) collected from organ donors 
through our donor transplant coordinators at the Addenbrooke’s Hospital, Cambridge, were handled in accord-
ance with the policies and procedures of the Human Tissue Act (UK) and with the approval of the Local and 
Regional Ethics Committees (MREC/03/2/074). Informed consent was taken from a family member, and all 
experiments performed in accordance with the relevant guidelines and regulations. Each arterial specimen 
was trimmed of blood vessels, any surrounding tissue and fat, and cut into 2 cm rings for biophysical measure-
ments. From each specimen, some tissue was taken for DNA analysis, some preserved in RNAlater® Stabilization 
Solution (AmbionTM #AM7021) for RNA and some for protein extractions. A further sample was fixed in forma-
lin and paraffin embedded (FFPE) for immunohistochemical investigations.
Biophysical measurements and study design. Aortic stiffness was measured as Young’s Elastic 
Modulus (EM)66, ex vivo using the tensile test machine (Instron® model 5500 R, United Kingdom) in 220 donor 
aortic rings. Briefly, each ring was cycled 5 times in the range of 0–200 mmHg at a rate of mm*min-l. EM at a load 




, where h 
is the wall thickness, r is arterial radius measured with a digital callipers and ρ is blood density taken as 1.05 g/
cm3. Study design for validation studies is illustrated in Fig. 1. For this ex vivo study, ascending and descending 
thoracic aortic samples from185 donors were used, as these segments differ histologically and embroyologically 
from the rest of the aorta. Of these donors, less than 10% were treated for CVD. We adopted the 
extreme-phenotype study design67, and pre-selected samples for lowest (n = 32) and highest (n = 28) EM values. 
Donors with EM readings of <0.1 MPa were grouped as ‘Low EM’ and those with EM readings of ≥0.25 MPa 
were grouped as ‘High EM’. Similarly, where donor aortae were stratified by age, individuals ≤32 years (n = 10) 
were classified as ‘Young’ and those >60 years (n = 10) were classified as ‘Old’.
Statistical Analysis. Data were analyzed using IBM SPSS Statistics (version 23) and GraphPad Prism (ver-
sion 7) software. One-way analysis of variance (ANOVA) with post-hoc testing compared the differences for 
continuous parameters and x2 testing compared differences for categorical variables. SNPs were tested for their 
association with aPWV by stepwise linear regression using an additive model after adjusting for confounding 
factors associated with aPWV, and the specific portion of variance explained by an R2 change. Unpaired t-test 
with Welch’s correction were used to compare differences between the two homozygous allele carriers of SNPs 
and their transcript levels. All the values are expressed as means ± SD in tables, and means ± SEM in figures. A 
probability value of <0.05 was considered significant.
For ACAN and FBLN-1 western blot quantifications, statistical significance between groups was determined 
using non-parametric Mann-Whitney U test. Fold difference in ACAN and FBLN-1 gene expression between 
low and high EM donor samples was calculated using the 2−ΔCt method where ΔCt = ACAN Ct – GAPDH Ct or 
FBLN-1 Ct – GAPDH Ct, and statistical significance between low EM and high EM samples determined using 
the two-tailed Student’s t-test68. A post-hoc ANCOVA analysis was performed to account for confounding effect 
of age between the two groups.
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